# Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

Study · id `cardio:ct-nct02217501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02217501](<https://clinicaltrials.gov/study/NCT02217501>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02217501

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT02217501. Randomized; no masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2020-01-30 (actual). Results posted on 2021-02-21.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Start date: 2015-11 (registry gives no type) (ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Primary completion: 2020-01-30 (actual) (ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Completion: 2020-01-30 (actual) (ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Results first posted: 2021-02-21 (ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02217501, source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02217501-2021-02-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
- Acronym: ASPIRE
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Acetylsalicylic acid (ASA)
- Lead sponsor: University of Texas Southwestern Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: University of Texas Southwestern Medical Center (`cardio:org-university-of-texas-southwestern-medical-center`)

## Provenance

Content hash: 185eddab7fe2e5af4619523155dfa9b77e44e5099c1971ead69c1a5b51d1432f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
